ZOE.F Zoetis Inc. R
Healthcare · Drug Manufacturers - Specialty & Generic
61.76
-1.37%
Über das Unternehmen
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
52-Wochen-Spanne
Dividenden-Tiefenanalyse
Zoetis Inc., a Healthcare sector company specializing in Drug Manufacturers - Specialty & Generic, currently offers a dividend yield of 2.95% in EUR. This yield is significantly above its 5-year average of 0.87% and its 5-year high of 1.35%. Valuation analysis suggests the stock is currently undervalued according to Yield Theory, though its fair value calculation indicates the price is 4.6% above fair value, suggesting a "fair" margin of safety. Momentum and value scores are not available, nor is an overall rating score.
Dividendenhistorie
Zoetis has a history of consistent dividend increases, maintaining a streak of 12 consecutive years. The company has demonstrated strong dividend growth with a 3-year compound annual growth rate (CAGR) of 15.44% and a 5-year CAGR of 20.11%. Annual dividends per share in EUR have increased steadily: 0.2539 in 2014, 0.3703 in 2017, 0.5783 in 2019, 0.8816 in 2021, 1.1461 in 2022, 1.3224 in 2023, and projected to 1.7632 in 2025. It is recognized as a Dividend Contender.
Dividendensicherheit
The dividend appears well-covered with a payout ratio of 33.77% based on earnings per share. In terms of leverage, Zoetis has a debt-to-equity ratio of 293.996%.
Quantic · Kostenlos
Lies den Rest zur Dividendensicherheit
Dazu die wichtigsten Risiken und worauf als Nächstes zu achten ist. Kostenlos, ohne Karte.
KI-generiert aus den Dividendendaten von Quantic · Aktualisiert am 29 Sep 2026 · Nur zur Information – keine Finanzberatung.
Auf Englisch angezeigt — eine Übersetzung folgt in Kürze.
Kursverlauf
Dividendenprofil
Rendite-Spanne Die aktuelle Dividendenrendite einer Aktie im Vergleich zu ihrer eigenen Spanne der letzten fünf Jahre — Tief, Durchschnitt und Hoch. Nahe am Hoch wirken die Aktien relativ günstig für die gezahlten Erträge; nahe am Tief relativ teuer. Es ist das Bild hinter der Dividend Yield Theory. Mehr erfahren → (5 Jahre)
Zahlungskalender
Dividendenhistorie
Dividende je Aktie nach Jahr
Verschuldung & Hebel
Zuletzt gemeldete Bilanzkennzahlen.
von 1 beobachtet
Erscheint in diesen Listen
ZOE.F erfüllt die Kriterien dieser Dividenden-Rankings.
Neu bei der Dividendenanlage?
Nur zur Information – keine Finanzberatung.
Quantic · Kostenlos
Verfolge ZOE.F und dein ganzes Portfolio
Echte Rendite, Dividendensicherheit, Nettoeinkommen nach Steuern und dein Weg zur Freiheit — kostenlos, ohne Broker-Verbindung.
Brauchst du mehr? Pro bringt mehr Portfolios, Optionseinkommen-Tracking und mehr KI. Pro ansehen →